James C. Yao, MD

Peer-Reviewed Articles

1. Sewastjanow-Silva M, Xiao L, Gonzalez GN, Wang X, Hofstetter W, Swisher S, Mehran R, Sepesi B, Bhutani MS, Weston B, Coronel E, Waters RE, Rogers JE, Smith J, Lyons L, Reilly N, Yao JC, Ajani JA, Murphy MB. Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study. Cancers (Basel) 16(7), 2024. e-Pub 2024. PMID: 38611056.
2. Tran Cao HS, Witt RG, Elsayes KM, Baiomy AA, Xiao L, Palmquist S, Lee SS, Mohamed YI, Mahvash A, Tzeng CD, Chun YS, Koay EJ, Rashid A, Hassan MM, Yao JC, Vauthey JN, Kaseb AO. Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features. Oncologist. e-Pub 2023. PMID: 38159256.
3. Shih YT, Xu Y, Yao JC. Financial Outcomes of "Bagging" Oncology Drugs Among Privately Insured Patients With Cancer. JAMA Netw Open 6(9):e2332643, 2023. e-Pub 2023. PMID: 37676663.
4. Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BR, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, Goodman KA, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, Reidy-Lagunes DL, Soares HP, Strosberg JR, Kohn EC, Kunz PL, NET CTPM participants. Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Natl Cancer Inst 115(9):1001-1010, 2023. PMID: 37255328.
5. Noh S, Bertini C, Mira-Avendano I, Kaous M, Patel B, Faiz SA, Shannon VR, Balachandran DD, Bashoura L, Adachi R, Evans SE, Dickey B, Wu C, Shroff GS, Manzano JG, Granwehr B, Holloway S, Dickson K, Mohammed A, Muthu M, Song H, D3CODE Team, Chung C, Wu J, Lee L, Jiang Y, Khawaja F, Sheshadri A. Interstitial lung abnormalities after hospitalization for COVID-19 in patients with cancer: A prospective cohort study. Cancer Med. e-Pub 2023. PMID: 37592894.
6. Liu Y, Wei D, Deguchi Y, Xu W, Tian R, Liu F, Xu M, Mao F, Li D, Chen W, Valentin LA, Deguchi E, Yao JC, Shureiqi I, Zuo X. PPARδ dysregulation of CCL20/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment. Gastric Cancer. e-Pub 2023. PMID: 37572185.
7. Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, García-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csoszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C, FRESCO-2 Study Investigators. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet 402(10395):41-53, 2023. e-Pub 2023. PMID: 37331369.
8. Chamseddine S, Mohamed YI, Lee SS, Yao JC, Hu ZI, Tran Cao HS, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Datar S, Amin HM, Kaseb AO. Clinical and Prognostic Biomarker Value of Blood Circulating Inflammatory Cytokines in Hepatocellular Carcinoma. Oncology. e-Pub 2023. PMID: 37467732.
9. Osterman TJ, Yao JC, Krzyzanowska MK. Implementing Innovation: Informatics-Based Technologies to Improve Care Delivery and Clinical Research. Am Soc Clin Oncol Educ Book 43:e389880, 2023. PMID: 37216629.
10. Reddy DR, Cuenca JA, Botdorf J, Muthu M, Hanmandlu A, Wegner R, Crommett J, Gutierrez C, Rathi N, Sajith B, Knafl M, Abbas HA, Woodman SE, Nates JL, D3CODE Team Collaborators. Clinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19. Mayo Clin Proc 98(3):451-457, 2023. e-Pub 2022. PMID: 36868753.
11. Halperin DM, Liu S, Dasari A, Fogelman D, Bhosale P, Mahvash A, Estrella JS, Rubin L, Morani AC, Knafl M, Overeem TA, Fu SC, Solis LM, Parra Cuentas E, Verma A, Chen HL, Gite S, Subashchandrabose P, Dervin S, Schulze K, Darbonne WC, Yun C, Wistuba II, Futreal PA, Woodman SE, Yao JC. Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial. JAMA Oncol 8(6):904-909, 2022. e-Pub 2022. PMID: 35389428.
12. Liu Y, Deguchi Y, Wei D, Liu F, Moussalli MJ, Deguchi E, Li D, Wang H, Valentin LA, Colby JK, Wang J, Zheng X, Ying H, Gagea M, Ji B, Shi J, Yao JC, Zuo X, Shureiqi I. Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ. Nat Commun 13(1):2665, 2022. e-Pub 2022. PMID: 35562376.
13. Hicks RJ, Dromain C, de Herder WW, Costa FP, Deroose CM, Frilling A, Koumarianou A, Krenning EP, Raymond E, Bodei L, Sorbye H, Welin S, Wiedenmann B, Wild D, Howe JR, Yao J, O'Toole D, Sundin A, Prasad V. ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. J Neuroendocrinol 34(3):e13040, 2022. e-Pub 2021. PMID: 34668262.
14. Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, Jindal S, Duan F, Basu S, Yadav SS, Nicholas C, Sun JJ, Singh Raghav KP, Rashid A, Carter K, Chun YS, Tzeng CD, Sakamuri D, Xu L, Sun R, Cristini V, Beretta L, Yao JC, Wolff RA, Allison JP, Sharma P. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 7(3):208-218, 2022. e-Pub 2022. PMID: 35065057.
15. Rogers JE, Lam M, Halperin DM, Dagohoy CG, Yao JC, Dasari A. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. Neuroendocrinology 112(1):34-42, 2022. e-Pub 2021. PMID: 33434908.
16. Pudakalakatti S, Titus M, Enriquez JS, Ramachandran S, Zacharias NM, Shureiqi I, Liu Y, Yao JC, Zuo X, Bhattacharya PK. Identifying the Metabolic Signatures of PPARD-Overexpressing Gastric Tumors. Int J Mol Sci 23(3):1645, 2022. e-Pub 2022. PMID: 35163565.
17. Monlezun DJ, Badalamenti A, Javaid A, Marmagkiolis K, Honan K, Kim JW, Patel R, Akhanti B, Halperin D, Dasari A, Koutroumpakis E, Kim P, Lopez-Mattei J, Yusuf SW, Cilingiroglu M, Mamas MA, Gregoric I, Yao J, Hassan S, Iliescu C. Artificial intelligence-augmented analysis of contemporary procedural, mortality, and cost trends in carcinoid heart disease in a large national cohort with a focus on the "forgotten pulmonic valve". Front Cardiovasc Med 9:1071138, 2022. e-Pub 2023. PMID: 36843627.
18. Voong KR, Rashid A, Crane CH, Minsky BD, Krishnan S, Yao JC, Wolff RA, Skibber JM, Feig BW, Chang GJ, Das P. Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal. Am J Clin Oncol 40(6):555-560, 2017. e-Pub 2015. PMID: 26237193.
19. Raghav KP, Mahajan S, Yao JC, Hobbs BP, Berry DA, Pentz RD, Tam A, Hong WK, Ellis LM, Abbruzzese J, Overman MJ. From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. J Clin Oncol 33(31):3583-90, 2015. e-Pub 2015. PMID: 26304898.
20. Halperin DM, Lee JJ, Dagohoy CG, Yao JC. Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials. J Clin Oncol 33(26):2914-9, 2015. e-Pub 2015. PMID: 26261263.
21. Shen C, Shih YT, Xu Y, Yao JC. Octreotide LAR among elderly patients with neuroendocrine tumors: A Survival analysis of SEER-Medicare data. Cancer Epidemiol Biomarkers Prev. e-Pub 2015. PMID: 26315553.
22. Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC, Kulke MH. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol 16(6):695-703, 2015. e-Pub 2015. PMID: 25956795.
23. Ng CS, Hobbs BP, Wei W, Anderson EF, Herron DH, Yao JC, Chandler AG. Effect on Perfusion Values of Sampling Interval of Computed Tomographic Perfusion Acquisitions in Neuroendocrine Liver Metastases and Normal Liver. J Comput Assist Tomogr 39(3):373-82, 2015. e-Pub 2015. PMID: 25626401.
24. Dasari A, Phan A, Gupta S, Rashid A, Yeung SC, Hess K, Chen H, Tarco E, Chen H, Wei C, Anh-Do K, Halperin DM, Meric-Bernstam F, Yao JC. Phase I study of cixutumumab with everolimus and octreotide LAR in advanced neuroendocrine carcinoma. Endocr Relat Cancer. e-Pub 2015. PMID: 25900182.
25. Lombard-Bohas C, Yao JC, Hobday T, Van Cutsem E, Wolin EM, Panneerselvam A, Stergiopoulos S, Shah MH, Capdevila J, Pommier R. Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-3 Trial. Pancreas 44(2):181-9, 2015. e-Pub 2014. PMID: 25479584.
26. Yao JC, Phan AT, Hess K, Fogelman D, Jacobs C, Dagohoy C, Leary C, Xie K, Ng CS. Perfusion Computed Tomography as Functional Biomarker in Randomized Run-In Study of Bevacizumab and Everolimus in Well-Differentiated Neuroendocrine Tumors. Pancreas 44(2):190-7, 2015. e-Pub 2014. PMID: 25426617.
27. Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw 13(1):78-108, 2015. PMID: 25583772.
28. Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer 28:9, 2014. PMID: 24771552.
29. Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff PM. A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. BMC Cancer(14):561, 2014. PMID: 25086465.
30. Estrella JS, Broaddus RR, Mathews A, Milton DR, Yao JC, Wang H, Rashid A.. Progesterone receptor and PTEN expression predict survival in patients with low- and intermediate-grade pancreatic neuroendocrine tumors. Arch Pathol Lab Med 138(8):1027-36, 2014. PMID: 25076292.
31. Boyd AE, Deford LL, Mares JE, Leary CC, Garris JL, Dagohoy CG, Boving VG, Brook JP, Phan A, Yao JC. Improving the Success Rate of Gluteal Intramuscular Injections. Pancreas 42(5):878-82, 2013. e-Pub 2013. PMID: 23508015.
32. Landry CS, Lin HY, Phan A, Charnsangavej C, Abdalla EK, Aloia T, Nicolas Vauthey J, Katz MH, Yao JC, Fleming JB. Resection of At-Risk Mesenteric Lymph Nodes Is Associated with Improved Survival in Patients with Small Bowel Neuroendocrine Tumors. World J Surg 37(7):1695-700, 2013. e-Pub 2013. PMID: 23657749.
33. Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC. Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors. Pancreas 42(4):557-577, 2013. PMID: 23591432.
34. Yao JC, Lagunes DR, Kulke MH. Targeted Therapies in Neuroendocrine Tumors (NET): Clinical Trial Challenges and Lessons Learned. Oncologist 18(5):525-32, 2013. e-Pub 2013. PMID: 23615698.
35. Yao JC, Phan AT, Jehl V, Shah G, Meric-Bernstam F. Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience. Cancer Res 73(5):1449-53, 2013. e-Pub 2013. PMID: 23436795.
36. Overman MJ, Modak J, Kopetz S, Murthy R, Yao JC, Hicks ME, Abbruzzese JL, Tam AL. Use of research biopsies in clinical trials: are risks and benefits adequately discussed?. J Clin Oncol 31(1):17-22, 2013. e-Pub 2012. PMID: 23129736.
37. Serra S, Zheng L, Hassan M, Phan AT, Woodhouse LJ, Yao JC, Ezzat S, Asa SL. The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy. Cancer Res 72(22):5683-91, 2012. e-Pub 2012. PMID: 22986737.
38. Hess GP, Chen CC, Liu Z, Yao JC, Phan AT, Hill JW. Clinical Burden of Illness in Patients With Neuroendocrine Tumors. Pancreas 41(7):1058-62, 2012. e-Pub 2012. PMID: 22513292.
39. Balachandran A, Tamm EP, Bhosale PR, Katz MH, Fleming JB, Yao JC, Charnsangavej C. Venous tumor thrombus in nonfunctional pancreatic neuroendocrine tumors. AJR Am J Roentgenol 199(3):602-8, 2012. PMID: 22915400.
40. Kulke MH, Benson AB 3rd, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW 2nd, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA. Neuroendocrine tumors. J Natl Compr Canc Netw 10(6):724-64, 2012. PMID: 22679117.
41. Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas 41(3):461-6, 2012. PMID: 22422138.
42. Yao JC, Phan AT. Optimising Therapeutic Options for Patients with Advanced Neuroendocrine Tumours. European Oncology and Haematology 8(4):217-23, 2012. PMID: na.
43. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378(9808):2005-11, 2011. e-Pub 2011. PMID: 22119496.
44. Yao JC, Phan AT. Overcoming antiangiogenic resistance. Clin Cancer Res 17(16):5217-9, 2011. PMID: 21828238.
45. Kulke MH, Bendell J, Kvols L, Picus J, Pommier R, Yao J.. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol 4(1):29, 2011. PMID: 21672194.
46. Salazar R, Reidy-Lagunes D, Yao J.. Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer. Drugs 71(7):841-52, 2011. PMID: 21568362.
47. Kulke M, Siu L, Tepper J, Fisher G, Jaffe D, Haller D, Ellis L, Benedetti J, Bergsland E, Hobday T, Van Cutsen E, Pingpank J, Oberg K, Cohen S, Posner M, Yao, JC. Future Directions in the Treatments of Neuroendocrine Tumors:Consensus Report of the National Cancer Institute Neuroendocrine Clinical Trials Planning Meeting. J Clin Oncol 29(7):934-43, 2011. PMID: 21263089.
48. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 29(7):934-43, 2011. e-Pub 2011. PMID: 21263089.
49. Ng CS, Charnsangavej C, Wei W, Yao JC. Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy. AJR Am J Roentgenol 196(3):569-76, 2011. PMID: 21343498.
50. Capdevila J, Salazar R, Halperín I, Abad A, Yao JC.. Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors. Cancer Metastasis Rev Suppl 1:27-34, 2011. PMID: 21311955.
51. Lebwohl D, Thomas G, Lane HA, O'Reilly T, Escudier B, Yao JC, Pavel M, Franz D, Berg W, Baladi JF, Stewart J, Motzer RJ. Research and innovation in the development of everolimus for oncology. Expert Opin Drug Discov 6(3):323-38, 2011. PMID: 22647206.
52. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K, RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for Advanced Pancreatic Neuroendocrine Tumors. N Engl J Med 364(364(6)):514-23, 2011. PMID: 21306238.
53. Walsh KM, Choi M, Oberg K, Kulke MH, Yao JC, Wu C, Jurkiewicz M, Hsu LI, Hooshmand SM, Hassan M, Janson ET, Cunningham JL, Vosburgh E, Sackler RS, Lifton RP, Dewan AT, Hoh J. A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum. Endocr Relat Cancer 18(1):171-80, 2011. e-Pub 2011. PMID: 21139019.
54. Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, Nutting C, Bushnell DL, Caplin ME, Yao JC, North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas 39(6):753-66, 2010. PMID: 20664473.
55. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. J Clin Oncol 28(1):69-76, 2010. e-Pub 2009. PMID: 19933912.
56. Clark OH, Ajani JA, Benson AB 3rd, Berlin JD, Blaszkowsky LS, Byrd D, Choti MA, Doherty GM, Engstrom PF, Gibbs JF, Heslin MJ, Kandeel F, Kessinger A, Kulke MH, Kunz P, Kvols L, Olson JA Jr, Ratliff TW, Salem R, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, Yao JC. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine Tumors. J Natl Compr Canc Netw 7(7):712, 2009. PMID: 19635226.
57. Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, Jia Z, Li Q, Yao JC, Xie K. Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer. Clin Cancer Res 15(5):1078-0432, 2009. PMID: 19223493.
58. Badgwell B, Cormier JN, Xing Y, Yao JC, Bose D, Krishnan S, Pisters P, Feig B, Mansfield P. Attempted salvage resection for recurrent gastric or gastroesophageal cancer. Ann Surg Oncol 16(4):1074-1076, 2009. PMID: 18985270.
59. Phan AT, Yao JC. Neuroendocrine tumors: novel approaches in the age of targeted therapy. Oncology 22(14):1617-23, 2008. PMID: 19198220.
60. Scott LC, Yao JC, Benson AB 3rd, Thomas AL, Falk S, Mena RR, Picus J, Wright J, Mulcahy MF, Ajani JA, Evans TR. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Chemother Pharmacol 63(2):363-70, 2008. PMID: 18398613.
61. Truong CD, Li W, Feng W, Cagle P, Khoury T, Alrawi S, Xie K, Yao J, Tan D. Alpha-Methylacyl-CoA Racemase Expression is Upregulated in Gastric Adenocarcinoma: A Study of 249 Cases. Int J Clin Exp Pathol 1(6):518-523, 2008. PMID: 18787636.
62. Wang L, Guan X, Zhang J, Jia Z, Wei D, Li Q, Yao J, Xie K. Targeted inhibition of Sp1-mediated transcription for antiangiogenic therapy of metastatic human gastric cancer in orthotopic nude mouse models. Int J Oncol 33(1):161-7, 2008. PMID: 18575762.
63. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess KR, Gupta S, Jacobs C, Mares J, Landgraf A, Rashid A, Meric-Bernstam F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study. J Clin Oncol 26(26):4311-4318, 2008. PMID: 18779618.
64. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdallas E, Fleming JB, Vauthey JN, Rashid A, Evans DB. One Hundred Years After Carcinoid: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. J Clin Oncol 26(18), 2008. PMID: 18565894.
65. Hassan MM, Phan A, Li D, Dagohoy, CG, Leary C, Yao JC. Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiology Biomarkers Prev 17(4):959-65, 2008.
66. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26(8):1316-23, 2008. e-Pub 2008. PMID: 18323556.
67. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 15(1):257-66, 2008. e-Pub 2008.
68. Murthy R, Kamat P, Nunez R, Madoff DC, Gupta S, Salem R, Yao JC. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol 19(1):145-51, 2008. e-Pub 2008.
69. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22(23):4762-71, 2004. PMID: 15570077.

Invited Articles

1. Halperin DM, Kulke MH, Yao JC. A Tale of Two Tumors: Treating Pancreatic and Extrapancreatic Neuroendocrine Tumors. Annu Rev Med 66:1-16, 2015. e-Pub 2014. PMID: 25341008.
2. Dasari A, Yao JC. Gastrointestinal neuroendocrine tumors: slow but steady progress. Oncology, 2014. PMID: 25224473.
3. Lewis MA, Yao JC. Molecular pathology and genetics of gastrointestinal neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes 1:22-7, 2014. PMID: 24310147.
4. Yao JC, Meric-Bernstam F, Lee JJ, Eckhardt SG.. Accelerated Approval and Breakthrough Therapy Designation: Oncology Drug Development on Speed?. Clin Cancer Res 19(16):4305-4308, 2013. e-Pub 2013. PMID: 23833307.
5. Metz DC, Choi J, Strosberg J, Heaney AP, Howden CW, Klimstra D, Yao JC. A rationale for multidisciplinary care in treating neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes 19(4):306-313, 2012. PMID: 22760514.
6. Dong M, Phan AT, Yao JC. New strategies for advanced neuroendocrine tumors in the era of targeted therapy. Clin Cancer Res 18(7):1830-6, 2012. e-Pub 2012. PMID: 22338018.
7. Yao JC, Hoff PM. Molecular targeted therapy for neuroendocrine tumors. Hematol Oncol Clin North Am 21(3):575-81, 2007. PMID: 17548041.

Abstracts

1. Arvind Dasari*, Sara Lonardi*, Rocio Garcia-Carbonero, Elena Elez, Takayuki Yoshino, Alberto Sobrero, James Yao, Pilar García-Alfonso, Judit Kocsis, Antonio Cubillo Gracian, Andrea Sartore-Bianchi, Taroh Satoh, Violaine Randrian, Jiri Tomasek, Geoff Chong, Andrew Scott Paulson, Toshiki Masuishi, Jeremy Jones, Tibor Csőszi, Chiara Cremolini, Francois Ghiringhelli, Ardaman Shergill, Howard S Hochster, John Krauss, Ali Bassam, Michel Ducreux, Anneli Elme, Laurence Faugeras, Stefan Kasper, Eric Van Cutsem, Dirk Arnold, Shivani Nanda, Zhao Yang, William R Schelman, Marek Kania, Josep Tabernero†, Cathy Eng†. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet 23, 2023.
2. Shen C, Shih T, Xu Y, Yao JC. Octreotide LAR (OCT-L) among elderly patients with stage IV neuroendocrine tumors (NETs): A survival analysis of SEER-Medicare data. 2014 ASCO ANNUAL MEETING(J Clin Oncol 32:5s, 2014 (suppl; abstr 4112)), 2014.
3. Rugo HS, Yao JC, Hortobagyi GN, Pavel ME, Franz DN, Ravaud A, Taran T, Gallo J, Rouyrre N, Anak O, Motzer RJ. Meta-analysis of stomatitis incidence in everolimus (EVE) clinical studies and its relationship with efficacy. 2014 ASCO ANNUAL MEETING(J Clin Oncol 32:5s, 2014 (suppl; abstr 645)), 2014.
4. Roland CL, Kang Y, Chatterjee D, Estrella J, Rashid A, Lee JE, Yao JC, Fleming JB. Loss of SMAD4 and effect on overall survival in resected gastrointestinal neuroendocrine tumors. 2014 GI ASCO(J Clin Oncol 32, 2014 (suppl 3; abstr 250)), 2014.
5. Conte B , George B, Dasari A, Overman MJ, Estrella J, Jiang Z, Machado K, Mello CL, Ferrarotto R, Hoff PM, Yao JC, Rashid A, Kopetz ES. Colorectal high-grade neuroendocrine carcinoma: A single institution experience. 2014 GI ASCO(J Clin Oncol 2014 (suppl 3; abstr 540)), 2014.
6. Dasari A, Phan AT, Gupta S, Hess KR, Culotta KS, Rashid A, Yeung SJ, Chen HX, Dong M, Halperin DM, Subbiah IM, Meric-Bernstam F, Yao JC. A phase I study of the anti-IGF-1R monoclonal antibody (MoAb), IMC-A12 (I), and everolimus (E) in well-differentiated neuroendocrine tumors (WD NET). 2014 GI ASCO(J Clin Oncol 32, 2014 (suppl 3; abstr 232)), 2014.
7. Strosberg JR, Yao JC, Bajetta E, Aout M, Bakker B, Hainsworth JD, Ruszniewski PB, Van Cutsem E, Oberg KE, Pavel ME. Efficacy of octreotide LAR (OCT) in patients (pts) with advanced neuroendocrine tumors (NET): A post hoc analysis of the placebo (PBO) arm of the phase III RADIANT-2 study with updated survival data. 2014 GI ASCO(J Clin Oncol 32, 2014 (suppl 3; abstr 265)), 2014.
8. Shih YT, Xu Y, Leary C, Yao JC. Factors associated with octreotide LAR use among elderly patients with carcinoid syndrome: A population-based analysis. 2012 ASCO Annual Meeting(J Clin Oncol), 2012.
9. Yao JC, Hainsworth JD, Wolin EM, Pavel ME, Baudin E, Gross D, Ruszniewski P, Tomassetti P, Panneerselvam A, Saletan S, Klimovsky J. Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET). 2012 ASCO Annual Meeting(J Clin Oncol), 2012.
10. Yao, JC. Effect of Everolimus Treatment on Markers of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET): Results From the Phase III RADIANT-3 Study. 2011 European Multidisciplinary Cancer Congress, 2011.
11. Pavel M, Hainsworth JD, Baudin E, Peeters M, Hoersch D, Anthony L,Hoosen S, St. Peter J, Jehl V, Yao JC. A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial of Everolimus 1 Octreotide LAR vs. Placebo 1 Octreotide LAR in Patients with Advanced Neuroendocrine Tumors (NET) (RADIANT-2). European Society of Medical Oncology (ESMO) Congress 2011, 2010.
12. Yao JC, Shah MH, Ito T, Lombard-Bohas C, Wolin EM, Van Cutsem E, Sachs C, Hoosen S, Lincy J, Hobday T. A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Tumors (PNET) (RADIANT-3). European Society for Medical Oncology (ESMO) Congress 2011, 2010.
13. Yao JC, Beaumont JL, Cella D, Choi S, Liu Z, Phan AT. Characteristics Associated with Health-Related Quality of Life of Patients with Neuroendocrine Tumor (NET). European Society of Medical Oncology (ESMO) Congress 2010, 2010.
14. O¨ berg K, Kulke M, Pavel M, Phan AT, Hoosen S, St. Peter J, Cherfi A, Yao JC. Prognostic and Predictive Value of Chromogranin A and Neuron-specific Enolase in Patients (PTS) with Advanced Pancreatic Neuroendocrine Tumors (PNET) Treated with Everolimus. European Society of Medical Oncology (ESMO) Congress 2010, 2010.
15. Stern L, Arora S, Willet J, Wang X, Liu Z, Yao JC. A Systematic Review of Epidemiology, Treatment Pattern, Economic and Humanistic Studies in Advanced Neuroendocrine Tumors. European Society of Medical Oncology (ESMO) Congress 2010, 2010.
16. Mani MA, Shroff RT, Jacobs CB, Wolff RA, Ajani JA, Yao JC, Phan AT. A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma. Journal of Clinical Oncology, 2008 ASCO Annual Meeting 26, 2008.

Book Chapters

1. Yao JC, Clarke CN, Evans DB. Pancreatic Neuroendocrine Tumors. In: CANCER Principles & Practice of Oncology. 11th Edition. Wolters Kluwer: Philadelphia, PA, 1352-1367, 2019.
2. Schmidt C, Blum Murphy M, Yao JC, Crane CH. Carcinoma of the stomach. In: Cancer Medicine. 9th Edition. WILEY Blackwell: Hoboken, New Jersey, 1091-1101, 2017.
3. Yao JC, Rindi G, Evans DB. Pancreatic Neuroendocrine Tumors. In: CANCER Principles & Practice of Oncology. 9th Edition. Wolters Kluwer: Philadelphia, PA, 1489-1502, 2011.
4. Yao JC, Rindi G, Evans DB. Pancreatic Endocrine Tumors. In: CANCER Principles & Practice of Oncology. 8th Edition. DeVita, 2008.
5. Yao JC, Xie K. Development of Novel Therapeutic Agents for Neuroendocrine Tumors. In: A Century of Advances in Neuroendocrine Tumor Biology and Treatment. Felsenstein CCCP, 370-377, 2008.
6. Yao JC, Gupta S, Vauthey JN, Evans DB. Management of Nonfunctional Islet Cell - Carcinomas of the Pancreas. In: Advanced Therapy in Surgical Oncology. BC Decker Inc: Lewiston, New York, 443-448, 2008.

Books (edited and written)

1. Yao JC, Hoff PM, Hoff AO, et al. Neuroendocrine Tumors. In: Current Clinical Oncology. Ed(s) Yao JC, Hoff PM, Hoff AO. Humana Press, 2011.
2. Caplin M, Yao JC. Handbook of Gastroenteropancreatic and Thoracic NeuroendocrineTumours. Ed(s) Caplin M, Yao JC. Bio Scientifica: UK, 2011.

Letters to the Editor

1. Kulke MH, Bergsland EK, Yao JC. Glycemic Control in Patients with Insulinoma Treated with Everolimus. N Engl J Med 360: 195-197, 2009.
2. Yao JC, Kvols LK. Octreotide LAR in Carcinoid: How to Dose?. Pancreas 37: 337-338, 2008.